An influential Food and Drug Administration advisory committee on Friday rejected a plan to administer booster shots of Pfizer and BioNTech's Covid-19 vaccine to the general public, saying they needed more data.
The panel, however, could still clear the shots for older populations. Scientists continued debating the need for a third dose of the vaccines for people 60 and older after their initial vote, leaving open the possibility of other votes.
The nonbinding decision by the FDA's Vaccines and Related Biological Products Advisory Committee comes as the Biden administration has said it wants to begin offering booster shots to the general public as early as next week, pending authorization from U.S. health regulators. While the agency hasn't always followed the advice of its committee, it often does. A final FDA decision could come in a matter of hours. The Centers of Disease Control and Prevention has scheduled a two-day meeting next week to discuss plans to distribute the third shots in the U.S.
The committee vote was expected to be a controversial one as some scientists, including two senior FDA officials who were involved in the meeting Friday, have said they aren't entirely convinced every American who has received the Pfizer vaccine needs extra doses right now.
In a paper published days before the advisory committee meeting, a leading group of scientists said available data showed vaccine protection against severe disease persists, even as the effectiveness against mild disease wanes over time. The authors, including two high-ranking FDA officials and multiple scientists from the World Health Organization, argued Monday in the medical journal The Lancet that widely distributing booster shots to the general public is not appropriate at this time.
FDA panel recommends Pfizer's Covid booster doses for people 65 and older after rejecting third shots for general population
Scientists continued debating the need for a third dose of the vaccines for older Americans, leaving open the possibility of other votes.
www.cnbc.com
Bloomberg states the vote was 16-2 against.
FDA Panel Backs Pfizer Booster for 65 and Up, Rejects Broad Use
The Covid-19 vaccine booster shot proposed by Pfizer Inc. and BioNTech SE should be given to older Americans and those at high risk, a panel of expert advisers to the U.S. Food and Drug Administration said, rejecting a request for broader distribution.
www.bloomberg.com
The FDA had asked the advisory panel to vote on whether the safety and effectiveness data submitted by the companies support approval of a booster dose for people age 16 and up. Panelists are discussing narrower options after rejecting that proposal in a 16-2 vote.
Some of the panelists indicated that while they see a potential need for older or other more vulnerable groups to receive a third dose, the need for younger people could be less pressing, and may pose other medical risks.
UPDATE: Boosters approved for those 65 and older. Rejected for general public / under 65 unless high risk.
Last edited: